Literature DB >> 22633904

RETRACTED: Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide.

Rajendra S Kadam1, Puneet Tyagi, Henry F Edelhauser, Uday B Kompella.   

Abstract

PURPOSE: One objective of this study was to determine whether polymeric nanoparticles and/or microparticles sustain transscleral choroidal and retinal delivery of triamcinolone acetonide (TA) for two months in therapeutically effective concentrations after single periocular administration. Another objective of this study was to assess the influence of choroidal neovascularization on transscleral delivery of TA.
METHODS: Polymeric nano- and micro-particles of TA were prepared by o/w emulsion-solvent evaporation method using poly-l-lactide (PLA). Particles were characterized for drug loading, size, surface morphology, and the in vitro drug release profile. Choroidal neovascularization (CNV) was induced in brown Norway (BN) rats using a 532 nm diode argon laser and the CNV induction was assessed using fluorescein angiography. In vivo delivery was assessed in control and CNV induced rats at 2 months after periocular injection of TA loaded nano- or micro-particle suspension, or plain TA suspension in PBS (pH 7.4). Ocular tissue levels of TA were estimated using LC-MS/MS following liquid-liquid extraction of drug from tissue samples. Nile red loaded microparticles entrapped in periocular tissue at the end of the study was visualized using scanning electron microscopy and confocal microscopy. Inhibitory effect of TA on VEGF secretion was evaluated in ARPE-19 cells.
RESULTS: Triamcinolone acetonide-PLA nano- (551 nm) and micro-particles (2090 nm), with 14.7 and 29.5% drug loading, respectively, sustained in vitro TA release for about 45 and 120 days. After subconjunctival injection, microparticles were able to sustain the delivery in all intraocular tissues for 2 months; whereas no drug levels were detected for TA loaded nanoparticles and plain suspension of TA. Intraocular delivery of TA from microparticles was higher in CNV induced rats when compared to control rats. Significant amount of microparticles remained in periocular tissue at 2 months after injection, and maintained spherical shape. TA decreased VEGF secretion by 50% at 0.07 μM. At the end of the in vivo study, choroid-RPE and retina TA levels in CNV induced rats were 16- and 5-fold higher than the IC(50) for VEGF secretion.
CONCLUSIONS: Single periocular injection of polymeric microparticles but not nanoparticles sustained effective levels of TA in choroid-RPE and retina for 2 months, with the TA delivery being greater in CNV induced rats than the control rats.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22633904      PMCID: PMC3573139          DOI: 10.1016/j.ijpharm.2012.05.025

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  31 in total

1.  Reduced foveolar choroidal blood flow in eyes with increasing AMD severity.

Authors:  Juan E Grunwald; Tatyana I Metelitsina; Joan C Dupont; Gui-Shuang Ying; Maureen G Maguire
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-03       Impact factor: 4.799

Review 2.  Age-related macular degeneration.

Authors:  Rama D Jager; William F Mieler; Joan W Miller
Journal:  N Engl J Med       Date:  2008-06-12       Impact factor: 91.245

3.  A new model of experimental choroidal neovascularization in the rat.

Authors:  E T Dobi; C A Puliafito; M Destro
Journal:  Arch Ophthalmol       Date:  1989-02

4.  Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation.

Authors:  H M Redhead; S S Davis; L Illum
Journal:  J Control Release       Date:  2001-02-23       Impact factor: 9.776

5.  Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization.

Authors:  K Spilsbury; K L Garrett; W Y Shen; I J Constable; P E Rakoczy
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

Review 6.  Recent advances in ophthalmic drug delivery.

Authors:  Uday B Kompella; Rajendra S Kadam; Vincent H L Lee
Journal:  Ther Deliv       Date:  2010-09

7.  Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes.

Authors:  Hee-Seung Chin; Tae-Sung Park; Yeon-Sung Moon; Jung-Hyub Oh
Journal:  Retina       Date:  2005 Jul-Aug       Impact factor: 4.256

8.  Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerve.

Authors:  Rajendra S Kadam; Uday B Kompella
Journal:  J Pharmacol Exp Ther       Date:  2009-11-19       Impact factor: 4.030

9.  Effect of eye pigmentation on transscleral drug delivery.

Authors:  Narayan P S Cheruvu; Aniruddha C Amrite; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01       Impact factor: 4.799

10.  Influence of Dll4 via HIF-1α-VEGF signaling on the angiogenesis of choroidal neovascularization under hypoxic conditions.

Authors:  Xiao Dong; Yu-Sheng Wang; Guo-Rui Dou; Hui-Yuan Hou; Yuan-Yuan Shi; Rui Zhang; Ke Ma; Lin Wu; Li-Bo Yao; Yan Cai; Jian Zhang
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

View more
  6 in total

Review 1.  Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.

Authors:  Uday B Kompella; Aniruddha C Amrite; Rashmi Pacha Ravi; Shelley A Durazo
Journal:  Prog Retin Eye Res       Date:  2013-04-17       Impact factor: 21.198

2.  Rationally designed nanocarriers for intranasaltherapy of allergic rhinitis: influence of carrier type on in vivo nasal deposition.

Authors:  Marwa Ahmed Sallam; Hala Mahmoud Helal; Sana Mohamed Mortada
Journal:  Int J Nanomedicine       Date:  2016-05-25

Review 3.  Nanotechnology approaches for ocular drug delivery.

Authors:  Qingguo Xu; Siva P Kambhampati; Rangaramanujam M Kannan
Journal:  Middle East Afr J Ophthalmol       Date:  2013 Jan-Mar

4.  Targeting inflammation in emerging therapies for genetic retinal disease.

Authors:  Ishaq A Viringipurampeer; Abu E Bashar; Cheryl Y Gregory-Evans; Orson L Moritz; Kevin Gregory-Evans
Journal:  Int J Inflam       Date:  2013-02-21

Review 5.  Particles from preformed polymers as carriers for drug delivery.

Authors:  K Miladi; D Ibraheem; M Iqbal; S Sfar; H Fessi; A Elaissari
Journal:  EXCLI J       Date:  2014-02-03       Impact factor: 4.068

6.  Polymerization-Induced Phase Separation Formation of Structured Hydrogel Particles via Microfluidics for Scar Therapeutics.

Authors:  S Guo; G Kang; D T Phan; M N Hsu; Y C Por; C H Chen
Journal:  Sci Rep       Date:  2018-02-02       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.